Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports

Chen Chen, Song Ran Liu, Shu Zhou, Xiao Hui Li, Xiao Hui Wang, Ya Lan Tao, Hui Chang, Wen Wen Zhang, Wen Fei Li, Si Lang Zhou, Yun Fei Xia

Research output: Contribution to journalArticle

Abstract

Rationale:Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.Patient concerns:Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.Diagnosis:They were diagnosed as refractory nasopharyngeal carcinoma.Interventions:A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.Outcomes:Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load.Lessons:Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.

Original languageEnglish (US)
Article numbere16592
JournalMedicine (United States)
Volume98
Issue number32
DOIs
StatePublished - Aug 1 2019

Fingerprint

Endostatins
Intravenous Infusions
Radiotherapy
Angiogenesis Inhibitors
Therapeutics
Combination Drug Therapy
Human Herpesvirus 4
Safety
Recurrence
Drug Therapy
Nasopharyngeal carcinoma
DNA
Neoplasms

Keywords

  • antiangiogenic agent
  • combined therapy
  • endostar
  • objective response rate
  • refractory nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma : Three case reports. / Chen, Chen; Liu, Song Ran; Zhou, Shu; Li, Xiao Hui; Wang, Xiao Hui; Tao, Ya Lan; Chang, Hui; Zhang, Wen Wen; Li, Wen Fei; Zhou, Si Lang; Xia, Yun Fei.

In: Medicine (United States), Vol. 98, No. 32, e16592, 01.08.2019.

Research output: Contribution to journalArticle

Chen, Chen ; Liu, Song Ran ; Zhou, Shu ; Li, Xiao Hui ; Wang, Xiao Hui ; Tao, Ya Lan ; Chang, Hui ; Zhang, Wen Wen ; Li, Wen Fei ; Zhou, Si Lang ; Xia, Yun Fei. / Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma : Three case reports. In: Medicine (United States). 2019 ; Vol. 98, No. 32.
@article{1397159c876b4283a869f09267b05416,
title = "Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports",
abstract = "Rationale:Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.Patient concerns:Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.Diagnosis:They were diagnosed as refractory nasopharyngeal carcinoma.Interventions:A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.Outcomes:Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load.Lessons:Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.",
keywords = "antiangiogenic agent, combined therapy, endostar, objective response rate, refractory nasopharyngeal carcinoma",
author = "Chen Chen and Liu, {Song Ran} and Shu Zhou and Li, {Xiao Hui} and Wang, {Xiao Hui} and Tao, {Ya Lan} and Hui Chang and Zhang, {Wen Wen} and Li, {Wen Fei} and Zhou, {Si Lang} and Xia, {Yun Fei}",
year = "2019",
month = "8",
day = "1",
doi = "10.1097/MD.0000000000016592",
language = "English (US)",
volume = "98",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "32",

}

TY - JOUR

T1 - Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

T2 - Three case reports

AU - Chen, Chen

AU - Liu, Song Ran

AU - Zhou, Shu

AU - Li, Xiao Hui

AU - Wang, Xiao Hui

AU - Tao, Ya Lan

AU - Chang, Hui

AU - Zhang, Wen Wen

AU - Li, Wen Fei

AU - Zhou, Si Lang

AU - Xia, Yun Fei

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Rationale:Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.Patient concerns:Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.Diagnosis:They were diagnosed as refractory nasopharyngeal carcinoma.Interventions:A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.Outcomes:Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load.Lessons:Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.

AB - Rationale:Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.Patient concerns:Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.Diagnosis:They were diagnosed as refractory nasopharyngeal carcinoma.Interventions:A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.Outcomes:Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load.Lessons:Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.

KW - antiangiogenic agent

KW - combined therapy

KW - endostar

KW - objective response rate

KW - refractory nasopharyngeal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85070545464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070545464&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000016592

DO - 10.1097/MD.0000000000016592

M3 - Article

C2 - 31393358

AN - SCOPUS:85070545464

VL - 98

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 32

M1 - e16592

ER -